JP Morgan analyst Geoff Meacham published a report on Vertex Pharmaceuticals VRTX that reiterated its Overweight rating and raised the price target from $82 to $86.
JP Morgan reported that, “Vertex's phase 3 strategy in F508del cystic fibrosis (CF) patients was recently
communicated with two trials, TRAFFIC and TRANSPORT, launching soon.
Surrounding this development, we spoke with a number of physicians and CFspecific
researchers, as well as reviewed the literature. We came away more
confident in the probability of success in phase 3, based on our feedback, and on
an updated SOTP analysis and sensitivity for the value of the VX-809 combo in
this population. Physicians we spoke to had a positive bias toward TRAFFIC /
TRANSPORT, noting a +2-4% change in FEV1 would be “clinically meaningful”
and would position the VX-809 / Kalydeco combo as a widely held standard of
care. Given this diligence, we are more confident in a positive outcome in phase 3
and are raising our VX-809 estimates. From a valuation perspective, our VX-809
scenario analysis suggests a favorable risk/reward with an aggregate total NPV
ranging from $63-118/share. As such, we are raising our YE13 PT to $86 from
$82 and reiterating our Overweight rating on VRTX shares. We will have much
more detail on our call (with slides) at 9 am ET TODAY: 888-889-1309 (US);
+1-773-756-0161 (OUS); Passcode: BIOTECH.”
Shares of Vertex Pharmaceuticals closed at $51.37 on Monday
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in